Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

Evangelista Sagnelli, Mariantonietta Pisaturo, Salvatore Martini, Pietro Filippini, Caterina Sagnelli, Nicola Coppola

Evangelista Sagnelli, Mariantonietta Pisaturo, Salvatore Martini, Pietro Filippini, Nicola Coppola, Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, 80131 Naples, Italy
Caterina Sagnelli, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, 80131 Naples, Italy

Author contributions: All authors contributed equally to this work.

Correspondence to: Evangelista Sagnelli, Professor, Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Via: L. Armanini 5, 80131 Naples, Italy, evangelista.sagnelli@yahoo.it
Telephone: +39-081-5666719 Fax: +39-081-5666013
Received: November 28, 2013 Revised: March 16, 2014 Accepted: May 31, 2014 Published online: June 27, 2014

Abstract
Occult hepatitis B infection (OBI), is characterized by low level hepatitis B virus (HBV) DNA in circulating blood and/or liver tissue. In clinical practice the presence of antibody to hepatitis B core antigen in hepatitis B surface antigen (HBsAg)-/anti-HBs-negative subjects is considered indicative of OBI. OBI is mostly observed in the window period of acute HBV infection in blood donors and in recipients of blood and blood products, in hepatitis C virus chronic carriers, in patients under pharmacological immunosuppression, and in those with immunodepression due to HIV infection or cancer. Reactivation of OBI mostly occurs in anti-HIV-positive subjects, in patients treated with immunosuppressive therapy in onco-hematological settings, in patients who undergo hematopoietic stem cell transplantation and in those treated with anti-CD20 or anti-CD52 monoclonal antibody. Reactivation may be severe and in nearly 20% of cases it may take a life-threatening course. The use of nucleot(s)ide analogues to prevent this reactivation is mandatory in hepatitis B surface antigen-negative/anti-hepatitis B core-positive patients in all conditions of strong and/or prolonged immunosuppression. We describe the characteristics of OBI in onco-hematological and rheumatological diseases, in solid cancers and in HIV infection.

Core tip: In occult Hepatitis B infection (OBI), hepatitis B virus reactivation is more common in anti-HIV-positive subjects, in those in onco-hematological settings, in patients who undergo hematopoietic stem cell transplantation and in those treated with anti-CD20 or anti-CD52 monoclonal antibody. Reactivation may be severe and in nearly 20% of cases it may take a life-threatening course. The use of nucleot(s)ide analogues to prevent this reactivation is mandatory in hepatitis B surface antigen-negative/anti-hepatitis B core-positive patients in all conditions of strong and/or prolonged immunosuppression. We describe the characteristics of OBI in onco-hematological and rheumatological diseases, in solid cancers and in HIV infection.

Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 2014; 6(6): 384-393 Available from: URL: http://www.wjgnet.com/1948-5182/full/
INTRODUCTION

Hepatitis B virus (HBV) infection is a major health problem in most countries, with approximately 2 billion people worldwide with serological evidence of previous exposure to the virus, of whom nearly 300 million have HBV chronic infection and over 1 million deaths per year are due to HBV-related cirrhosis and/or hepatocellular carcinoma (HCC)\(^1\-\(^6\).\)

HBV infection is identified in most cases by the presence of circulating hepatitis B surface antigen (HBsAg), but an HBsAg-negative HBV infection has also been described (Occult B infection (OBI))\(^7\), characterized by low levels of HBV DNA in circulating blood\(^8\-\(^9\) and/or in liver tissue\(^10\). OBI has also been described as a serological condition characterized by the presence of hepatitis B core antigen (anti-HBc) in the absence of HBsAg and anti-HBs (isolated anti-HBc)\(^11\-\(^15\). OBI may be observed in the window period of acute HBV infection\(^10\) in blood donors and in recipients of blood and blood products\(^16\-\(^19\), in patients with HCV chronic infection\(^\)\(^20\-\(^21\) in cryptogenic chronic hepatitis, in patients under pharmacological suppression of the immune system\(^22\-\(^23\) and in those with immunodepression due to HIV infection; it has also been associated to the development of hepatocellular carcinoma\(^24\-\(^29\).\)

It has been shown that the hepatitis B virus maintains its pro-oncogenic properties in OBI\(^30\) and that its presence in patients with chronic hepatitis C is associated with a higher risk of disease progression and HCC development\(^30\-\(^36\) and with a reduced response to alfa interferon treatment\(^30\-\(^36\). The clinical importance of OBI is also underscored by the need for nucleot(s)ide treatment to prevent the recurrence of HBV infection in HBsAg-negative/anti-HBc-positive patients in various immunosuppressive settings\(^30\-\(^40\).\)

This review article presents an up-to-date evaluation of the current knowledge on OBI, focusing in particular on the clinical approach in onco-hematological and rheumatological diseases, solid cancers and HIV infection.

OCCULT HBV INFECTION AND IMMUNOSUPPRESSION

Reactivation of HBV infection in patients under immunosuppressive treatment is a well-known, life-threatening event described in HBsAg-positive patients (overt HBV infection) and in subjects with OBI\(^10\-\(^11\,\(^21\-\(^23\). The reactivation of HBV infection, overt or occult, is characterized by a marked enhancement of viral replication during immunosuppressive therapy, with a wide spread of HBV to uninfected hepatocytes and a substantial increase in the HBV DNA serum level followed by the restoration of the immune function after treatment withdrawal and consequent cytotoxic-T-cell-mediated necrosis of HBV-infected hepatocytes usually responsible for a hepatic flare and in some instances for liver failure and even death\(^12\). A schematic representation of the dynamics of serum HBV DNA and alanine aminotransferase (ALT) before and during the reactivation of OBI is shown in Figure 1.

Both in overt and occult infection the risk of HBV reactivation is estimated as high when immunosuppression is marked, particularly in onco-hematological patients (21%-67%), in those receiving hematopoietic stem cell transplantation and in those treated with the anti-CD20 monoclonal antibody rituximab or with the monoclonal anti-CD52 antibody alemtuzumab, both responsible for profound, long-lasting immunosuppression\(^20\-\(^21\,\(^24\-\(^51\-\(^59\). Under these conditions HBV reactivation has a mortality rate close to 20%, due to a hepatic failure or to the progression of the underlying disease due to the discontinuation of specific treatment\(^51\,\(^60\-\(^61\). Besides host factors, also some virological characteristics have been described as possibly associated with HBV reactivation. In 7 of 84 HBsAg-negative/anti-HBc-positive patients treated for hematological diseases or solid cancer, HBV reactivation was due to non-A HBV genotypes, core promoter and/or precore HBV mutants. In these 7 patients mutations known to impair HBsAg antigenicity were also detected\(^62\). A precore stop mutation (A1896) was detected in one patient with genotype Bj who developed fulminant liver failure\(^63\). Also sub-genotype D1 has been described as possibly associated with HBV reactivation in two studies, one from Egypt and one from Italy\(^25\,\(^26\).

There is general agreement for the use of nucleot(s)ide analogues to prevent HBV reactivation in HBsAg-positive immunosuppressed patients, whereas it is still a matter of debate whether subjects with occult HBV infection should be treated or closely monitored for early treatment once HBsAg positivity has developed.

PHARMACOLOGICAL PROPHYLAXIS OF OCCULT HBV INFECTION IN DIFFERENT CLINICAL SETTINGS

Hematological diseases

A crucial role in the reactivation of OBI is played by the

---

**Figure 1** Virological and biochemical dynamics of reactivation of occult hepatitis B infection. HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBsAg: Hepatitis B surface antigen.

---

v6/i6/384.htm DOI: http://dx.doi.org/10.4254/wjh.v6.i6.384
severity and duration of immunosuppression, which in turn reflects the extent of immunodepression due to the hematological disease and of the degree of immunosuppression induced by chemotherapy. The drugs commonly responsible for HBV reactivation are those used in hematological malignancy, such as fludarabine, anthracyclines, high dose corticosteroids\cite{51,52}, and, more recently, rituximab (anti-CD20) and alemtuzumab (anti-CD52)\cite{53}.

Evidence has become available in hematological malignancy that the reactivation of occult HBV infection is frequent in patients treated with rituximab or fludarabine in the absence of lamivudine prophylaxis\cite{51,60,61}. However, due to the retrospective nature of most studies published, the geographical differences in HBV epidemiology and the genetic differences in HBV and the host have not been investigated, and the prevalence of HBV reactivation varies widely (from 3\% to 45\%)\cite{21,53,56,60,61}. The first prospective study\cite{41} on 244 occult HBV carriers with malignant lymphoma showed a reactivation in 8 (3.3\%) cases, with a higher risk of reactivation in patients receiving rituximab plus corticosteroids than in those under a rituximab-sparing schedule. In a prospective study on patients with diffuse large B-cell lymphoma (DLBCL), Yeoh et al\cite{71} reported reactivation of HBV infection in 5 of 21 (23.8\%) patients treated with rituximab plus cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP) and in none of the 25 patients receiving only CHOP. Recently Fukushima et al\cite{72} observed reactivation in 2 (4.1\%) of 48 HBsAg-negative/anti-HBc-positive patients. In addition, in 150 patients with lymphoma and a resolved HBV infection who received rituximab-based chemotherapy, Hsu et al\cite{73} described an incidence of HBV reactivation and of HBV hepatic flares of 10.4 and 6.4, respectively, per person per year. Matsu et al\cite{74} followed up for a median period of 20.5 mo 59 patients with isolated anti-HBc and lymphoma treated with rituximab-based chemotherapy and observed HBV reactivation in 4 (6.8\%).

Lower prevalences of HBV reactivation in HBsAg-negative patients after rituximab-based therapy have been reported in two studies from eastern Asia, 1.5\% and 4.2\%, respectively\cite{47,55,75}. In another Asian study only one (2.3\%) of 43 DLBCL patients treated with an R-CHOP regimen showed reactivation of HBV replication\cite{77}, for which a remission was obtained with antiviral therapy with no need to discontinue chemotherapy. Koo et al\cite{78} described HBV reactivation in two (3\%) of 62 HBsAg-negative/anti-HBc-positive patients treated with rituximab-based chemotherapy who did not undergo anti-HBV prophylaxis. More recently, the Asia Lymphoma Study Group investigated for HBV reactivation HBsAg-positive patients and HBsAg-negative/HBcAb-positive patients who received rituximab-based chemotherapy; the study was retrospective and performed on 340 patients, with a reactivation rate of 2.4\% in subjects with OBI and 27.8\% in HBsAg-positive patients\cite{79}.

The different frequency of cases with reactivation of occult HBV infection in different countries may explain, at least in part, the discordance in different national guidelines on lamivudine prophylaxis, some of which indicate the use of this nucleoside analogue for a pharmacological prophylaxis of HBsAg-negative/anti-HBc-positive patients undergoing highly immunosuppressive treatment for onco-hematological diseases\cite{60,61}, and others conclude that the information available does not allow any routine prophylaxis to be recommended for these patients\cite{71}.

The data of a recent meta-analysis, however, suggest that rituximab-based chemotherapy increases the risk of HBV reactivation in HBsAg-negative/anti-HBc-positive patients with non-Hodgkin lymphoma\cite{77}, an observation of clinical importance to be taken into consideration for future guidelines.

**Rheumatological disease**

Biological therapies targeting tumor necrosis factor-alpha (TNF-\(\alpha\)) have been used increasingly over the last decade to treat various immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease\cite{42}. Studies carried out over this period showed that monoclonal antibodies against TNF-\(\alpha\) (anti-TNF-\(\alpha\)) and high doses of steroid treatment may induce HBV reactivation in patients with overt HBV infection\cite{79,82}, thus suggesting the need for anti-HBV pharmacological prophylaxis for inactive HBsAg carriers\cite{80} and treatment for patients with HBsAg-positive chronic hepatitis.

The reactivation of OBI during anti-TNF therapy has not been extensively investigated and the data available are anecdotal and mostly from case reports. In a recent evaluation of the literature data, HBV reactivation was found in only 8 (1.7\%) of 468 HBsAg-negative/anti-HBc-positive patients with rheumatological diseases treated with anti-TNF\(\alpha\). In addition, none of 20 HBsAg-negative/HBV DNA-negative/anti-HBc-positive patients receiving anti-TNF-\(\alpha\) for rheumatoid arthritis and spondyloarthropathy experienced reactivation of OBI during a 4-year follow up\cite{62}.

**Solid cancers**

The literature data give evidence of HBV reactivation in HBsAg-positive patients treated with chemotherapy for solid tumors\cite{85-87}, and, consequently, pharmacological prophylaxis for inactive HBsAg carriers and therapy for patients with HBsAg-positive chronic hepatitis is recommended. Instead, the studies on HBV reactivation in patients with OBI are not conclusive, but so far no evidence of reactivation of OBI in these patients has emerged. The longitudinal study by Saitta et al\cite{79} on 44 HBsAg-negative patients with solid tumors undergoing chemotherapy did not find cases with HBV reactivation. Further prospective studies are needed to improve our knowledge of the clinical importance of OBI in patients with solid cancers.

**STRATEGIES TO PREVENT REACTIVATION OF OCCULT HBV INFECTION**

In patients with OBI, pharmacological prophylaxis with
nucleos(t)ide analogues should be based on the HBV serological status (anti-HBc-positive or -negative), the underlying diseases (onco-hematological diseases, hematopoietic stem cell transplantation or others) and the type of immunosuppressive treatment (rituximab, high doses of corticosteroids, anthracyclines, or others). In anti-HBc-positive patients, the prophylaxis with anti-HBV nucleos(t)ide analogues is indicated in hematopoietic stem cell transplantation and in onco-hematological diseases when high doses of corticosteroids and rituximab are used, whereas monitoring is indicated in all other clinical conditions or when rituximab-sparing schedules are used (Figure 2). The literature data have shown the efficacy of lamivudine in preventing HBV reactivation in these subsets of patients. Also entecavir has been proposed in the prophylaxis of reactivation of OBI. In a randomized controlled trial, 80 patients with CD20+ lymphoma and resolved hepatitis B were randomly assigned to a prophylactic schedule with entecavir, started before rituximab-based chemotherapy and stopped 3 mo after its discontinuation, or to be treated with entecavir once HBV reactivation and reversion to HBsAg positivity had occurred (control group). During an 18-mo follow up, HBV reactivation occurred in 2.4% of patients who underwent entecavir prophylaxis and in 17.9% of cases in the control group \((P < 0.05)\).

Although the efficacy of lamivudine and entecavir in preventing the reactivation of OBI has never been compared in published studies, we can conclude, in agreement with current international guidelines, that lamivudine, despite of its low genetic barrier, remains the nucleos(t)ide analogue of choice for the prophylaxis of reactivation of OBI because of its low cost and of the low or absent HBV viremia in OBI. Instead, entecavir should replace lamivudine for patients with advanced liver diseases for whom reactivation of OBI might be life threatening.

Monitoring of pharmacological prophylaxis is not standardized and the widespread habit of determining HBsAg at three-monthly intervals is not the optimal strategy in all clinical conditions. In addition, it is not fully understood how long the pharmacological prophylaxis should last in order to prevent the reactivation of HBV infection. Observational studies suggest extending the prophylaxis to the 12th month after the discontinuation of immunosuppressive treatment, but in some case reports HBV reactivation occurred later, especially in patients treated with rituximab. Recently, Tonziello et al described a reactivation of OBI in an HBsAg-negative/anti-HBc-positive woman with non-Hodgkin lymphoma occurring 20 mo after rituximab discontinuation despite lamivudine prophylaxis covering the 4 mo of rituximab administration and the 12 mo after its discontinuation. Concluding on this point, prospective studies are needed to ascertain whether the pharmacological prophylaxis should be extended to the 18th month after the discontinuation of immunosuppressive treatment in patients receiving rituximab-based chemotherapy.

**MANAGEMENT OF REACTIVATION OF OCCULT HBV INFECTION**

Once reactivation has occurred, effective antiviral treatment should be immediately administered. Lamivudine monotherapy has been demonstrated to be ineffective in reducing mortality. Consequently, patients should be treated with drugs of high potency and high genetic barrier such as entecavir or tenofovir.

**OCCULT HBV INFECTION IN HIV-POSITIVE SUBJECTS**

As a consequence of the availability of highly active antiretroviral therapy (HAART), which has determined a substantial improvement in the patients’ survival, vi-

---

**Figure 2** Management of occult hepatitis B infection in hematological and rheumatological diseases and in solid cancers.

- Entecavir instead of Lamivudine, when appropriate.
- HBsAg: Hepatitis B surface antigen; ALT: Alanine aminotransferase; Anti-HBc: Hepatitis B core antigen; TNF-α: Tumor necrosis factors-alpha.
Sagnelli E et al. Occult HBV infection in an immunosuppressive setting

HIV/anti-Hbc-positive patients

HBV DNA

HBV-DNA positive

HAART with 2 anti-HBV nucleos(t)ide analogues

Monitoring for HBsAg and ALT every 3 mo

HBV-DNA negative

Figure 3 Management of occult hepatitis B infection in anti-human immunodeficiency virus-positive subjects. HCV: Hepatitis C virus; ALT: Alanine aminotransferase; HBV: Hepatitis B virus; HAART: Highly active antiretroviral therapy; HBsAg: Hepatitis B surface antigen.

In recent years the prevalence of OBI has become the leading cause of morbidity and mortality in HIV-infected subjects. In these patients particular attention should be paid to OBI since it may have a strong clinical impact because of damage to the immune system and its frequent occurrence in HIV-HCV coinfected patients.

EPIDEMIOLOGY OF OBI IN HIV-POSITIVE SUBJECTS

The prevalence of OBI in HIV-infected patients is controversial, and the associated risk factors and the effect of HAART undefined. Also controversial is the role of the immune system in the genesis of OBI in HIV-positive patients. Some investigators never observed OBI in patients with CD4 counts > 500 cells/μL and concluded for a significant association of OBI with lower CD4 counts[9]. Other investigators, however, described no association of OBI with the CD4 count[26].

The prevalence of OBI in HIV-HCV coinfected patients varies in different studies from less than 1% to 40%[22,23,102].

OBI may also be observed in anti-HIV-positive patients with chronic HBV/HCV coinfection, due to an HBsAg serum clearance consequent to a strong inhibitory effect of the HCV genome on HBV replication[26].

In HIV subjects a strong association between OBI and HCV infection has been observed in several studies[28,101,104-106]. In contrast, Jardim et al[107] reported no significant difference in the rate of OBI in HIV-positive patients with or without HCV coinfection.

The discrepancies in the rate of OBI in the different studies most probably reflect differences in HBV, HCV and HIV epidemiology in different countries, a variation in the sensitivity of the assays used to detect HBV DNA and the retrospective nature of some of the studies.

Cassini et al[108] proposed a new approach to the detection of HBV DNA. By the genomic amplification of the partial S, X and precore/core regions, these Authors analyzed for the presence of HBV DNA the circulating blood, liver tissue and peripheral blood mononuclear cells (PBMC). HBV DNA was never found in serum samples of the 24 HBsAg-negative patients investigated, but was detected in the liver tissue in 7 (29%) and in PBMC in 6 (86%) of these 7. The clinical value of these data should be confirmed in larger studies, but they suggest that the detection of HBV DNA in PBMC offers a useful tool to identify OBI. Morsica et al[109] analyzed 1593 anti-HIV-positive patients enrolled in the Italian Cohort of Antiretroviral Naïve patients and found 175 (11%) HBsAg-negative/anti-HBe-positive patients: 27 of these 175 (15%) patients had detectable HBV DNA in plasma. This prevalence was significantly higher (21%) in the 101 anti-HCV-positive than in the 74 (8%) anti-HCV-negative, regardless of the immune status, HIV load, or ART regimen.

Clinical Significance of OBI in HIV-Positive Subjects

The impact of OBI on the prognosis of HIV-positive patients is still unclear. In our previous study[105] on the clinical and virological impact of OBI in HIV-positive patients, we analyzed 115 HBsAg-negative patients, 86 of whom were observed in a long-term follow-up. A hepatic flare occurred more frequently in the 17 patients with occult HBV infection than in the 69 without (64.7% vs 24.6%; P < 0.005). These preliminary data still await confirmation in larger studies.

Lamivudine-based HAART is effective in suppressing HBV replication even in anti-HIV-positive patients with OBI, as most of these cases clear HBV DNA during treatment. However, in approximately half of the lamivudine-treated patients, occult HBV replication became detectable again after 12-40 mo of lamivudine treatment, always associated with a hepatic flare. Although the presence of YMDD mutants in patients who became HBV-DNA-positive under lamivudine was not detected, most probably because of the low levels of plasma HBV DNA, the hypothesis that lamivudine induced the selection of YMDD mutants in these anti-HIV-positive subjects with OBI cannot be ruled out. In another study the ALT and aspartate aminotransferase levels showed a tendency to increase more frequently in patients with OBI than in those without[106].

Concluding on this point, OBI seems relatively frequent in anti-HIV-positive patients, particularly in cases with HIV/HCV co-infection. This makes the clinical condition of HIV/HCV co-infection more complex since OBI may unfavorably affect the outcome of the liver disease. Lamivudine seems inadequate for a long-term prevention of hepatic flares in anti-HIV-positive patients with OBI and possibly in reducing the risk of HBV oncogenicity. Therefore, for these patients a high potency, high genetic barrier nucleos(t)ide analogue should be preferred (Figure 3).

Conclusion

Clinicians should pay careful attention to OBI since it has...
been demonstrated that it may have some benefits and may have clinical consequences.

Further studies are needed to better define the biological and clinical role of OBI and to identify new measures to prevent or limit its unfavorable clinical action. It would be of particular benefit to investigate the oncogenicity of OBI, particularly in anti-HIV-positive subjects, in order to devise new strategies for the prevention of HCC.

REFERENCES

1. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34 Suppl 1: S1-S3 [PMID: 16461208 DOI: 10.1016/S1386-6532(05)00384-7]

2. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242 [PMID: 19054588 DOI: 10.1016/j.jhep.2009.02.017]

3. Murata K, Sugimoto K, Shiraki K, Nakano T. Relative predictive factors for hepatocellular carcinoma after HBsAg seroconversion in HBV infection. World J Gastroenterol 2005; 11: 6848-6852 [PMID: 16425959]

4. Ou DP, Yang LY, Huang GW, Tao YM, Ding X, Chang ZG. Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV. World J Gastroenterol 2005; 11: 2861-2866 [PMID: 15810869]

5. Sagnelli E, Stroffolini T, Mele A, Imparato M, Sagnelli C, Coppola N, Almasio PL. Impact of comorbidities on the severity of chronic hepatitis B at presentation. World J Gastroenterol 2012; 18: 1616-1621 [PMID: 22529690 DOI: 10.3748/wjg.v18.i14.1616]

6. Borgia G, Carleto MA, Gaeta GB, Gentile I. Hepatitis B in pregnancy. World J Gastroenterol 2012; 18: 4677-4685 [PMID: 23002366]

7. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-486 [PMID: 12158047 DOI: 10.1016/S1473-3099(02)00345-6]

8. Izmirli S, Celik DG, Yuksel P, Saribas S, Aylan M, Ergin S, Bahar H, Sen S, Cakal B, Oner A, Kocazeybek B. The detection of occult HBV infection in patients with HBsAg negative pattern by real-time PCR method. Transfus Apher Sci 2012; 47: 283-287 [PMID: 23021041 DOI: 10.1016/j.transci.2012.07.009]

9. Coppola N, Loquercio G, Tonziello G, Azzaro R, Pisaturo M, Di Costanzo G, Starace M, Pasquale G, Cacciapuoti C, Petruzziello A. HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol 2013; 58: 315-317 [PMID: 23856167 DOI: 10.1016/j.jcv.2013.06.020]

10. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxi A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrevo M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trope C, Villa E, Will H, Zanetti AR, Zoulim F. Detection of hepatitis B virus infection in pa...
Sagnelli E et al. Occult HBV infection in an immunosuppressive setting

26 Sheu JC, Huang GT, Shih LN, Lee WC, Chou HC, Wang JT, Lee PH, Lai MY, Wang CY, Yang PM. Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology 1992; 103: 1322-1327 [PMID: 13275342]

27 Pollinico T, Squadrito G, Cerenza G, Cacciola I, Raffa G, Craxi A, Farinatti F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-110 [PMID: 14699492 DOI: 10.1015/j.gastro.2003.10.048]

28 Squadrito G, Pollinico T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, Cucinotta E, Scsca C, Magazzu D, Raimondo G. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006; 106: 1326-1330 [PMID: 16435330 DOI: 10.1002/cncr.21702]

29 Coppola N, Pisapia R, Tonziello G, Martini S, Imparato M, Piai G, Stanzione M, Sagnelli C, Filippini P, Piccinino F, Sagnelli E. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus co-infection. Antivir Ther 2008; 13: 307-318 [PMID: 18505182]

30 Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, Piai G, Stanzione M, Bruno M, Moggio G, Caprio N, Pasquale G, Del Vecchio Blanco C. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol 2008; 80: 1547-1553 [PMID: 18649338]

31 Sagnelli E, Pasquale G, Coppola N, Marroccho C, Scarano F, Imparato M, Sagnelli C, Scolastico C, Piccinino F. Liver histology in patients with HBsAg negative anti-HBc and anti-HCV positive chronic hepatitis. J Med Virol 2005; 75: 222-226 [PMID: 15602732 DOI: 10.1002/jmv.20260]

32 Cacciola I, Pollinico T, Squadrito G, Cerenza G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-26 [PMID: 10587998 DOI: 10.1056/NEJM19990701341014]

33 Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and “silent” HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 2001; 64: 350-355 [PMID: 11424125 DOI: 10.1002/jmv.1057]

34 Chemin I, Leantet D, Kay A, Trépo C. Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease. Antiviral Res 2001; 52: 117-123 [PMID: 11672821 DOI: 10.1016/S0166-3542]

35 Mraai S, Chemin I, Menouar K, Guillaud O, Pradat P, Bogetti G, Traub MA, Chevallier P, Chevallier M, Zoulim F, Trabaud MA. Occult hepatitis B infection is associated with an increased risk of hepatocellular carcinoma among chronic hepatitis B patients. J Gastroenterol Hepatol 2010; 25: 864-871 DOI: 10.1111/j.1440-1746.2010.06243.x

36 Watanabe T, Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatology 2013; 43: 113-121 [PMID: 23186317 DOI: 10.1001/hep.12014]

37 Yagci M, Acar K, Suck GT, Akk Z, Bozdayi G, Haznedaroglu A. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues. Leuk Lymphoma 2006; 47: 1608-1612 [PMID: 16966273 DOI: 10.1080/10428190500472974]

38 Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, H iso-tomi T, Kuwahara N, Tomimasu R, TsuneoYoshi N, Funai N, Sueoka E. Retrospective and prospective studies of hepatitis B virus reactivation in patients with chronic hepatitis B carriers. J Gastroenterol Hepatol 2010; 25: 864-871 DOI: 10.1111/j.1440-1746.2010.06243.x

39 Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220 [PMID: 16440366 DOI: 10.1002/hep.20151]

40 Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008; 2: 152-162 [PMID: 19669300 DOI: 10.1007/s12077-008-9056-3]

41 Lubej JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010; 25: 864-871 DOI: 10.1111/j.1440-1746.2010.06243.x

42 Watanabe T, Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatology 2013; 43: 113-121 [PMID: 23186317 DOI: 10.1001/hep.12014]

43 Yagci M, Acar K, Sukac GT, Aki Z, Bozdayi G, Haznedaroglu A. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues. Leuk Lymphoma 2006; 47: 1608-1612 [PMID: 16966273 DOI: 10.1080/10428190500472974]

44 Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisato-tomi T, Kuhwahara N, Tomrmasu R, TsuneoYoshi N, Funai N, Sueoka E. Retrospective and prospective studies of hepatitis B virus reactivation in patients with chronic hepatitis B carriers. J Gastroenterol Hepatol 2010; 25: 864-871 DOI: 10.1111/j.1440-1746.2010.06243.x

45 Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89: 255-262 [PMID: 19697028 DOI: 10.1007/s00277-009-0806-7]

46 Palmore TN, Shah NL, Loomba R, Borng BB, Lopatin U, Feld JJ, Khokhar F, Luchman G, Young NS, Childs R, Acar K, Sucak GT, Aki Z, Bozdayi G, Haznedaroglu A. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues. Leuk Lymphoma 2006; 47: 1608-1612 [PMID: 16966273 DOI: 10.1080/10428190500472974]

47 Palmore TN, Shah NL, Loomba R, Borng BB, Lopatin U, Feld JJ, Khokhar F, Luchman G, Young NS, Childs R, Acar K, Sucak GT, Aki Z, Bozdayi G, Haznedaroglu A. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues. Leuk Lymphoma 2006; 47: 1608-1612 [PMID: 16966273 DOI: 10.1080/10428190500472974]

48 Liang R, How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. World J Gastroenterol 2014; 20: 65-68 [PMID: 11745931 DOI: 10.1002/jmv.2090]
June 27, 2014 | Volume 6 | Issue 6 | 391

Sagnelli E et al. Occult HBV infection in an immunosuppressive setting

**Blood** 2009; **113**: 3147-3153 [PMID: 19144986 DOI: 10.1182/blood-2008-10-163495]

54 Ustün C, Koç H, Karayalçın S, Akyol G, Gürtman G, Ilhan O, Akan H, Özcan M, Arslan Ö, Konuk N, Uysal A, Bekşan M. Hepatitis B virus infection in allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1997; **20**: 289-296 [PMID: 9285543 DOI: 10.1038/sj.bmt.1700885]

55 Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie AK, Kwong YL, Fong DY, Au WY, Kwong YL, Lie AK, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Khaled Y. Incidence of hepatitis B reactivation following rituximab therapy. *Am J Hematol* 2009; **84**: 195 [PMID: 19140189 DOI: 10.1002/ajh.21343]

56 Matsue K, Kimura S, Takehara Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. *Cancer* 2010; **116**: 4769-4776 [PMID: 20597095 DOI: 10.1002/cncr.25725]

57 Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Koo YX, Chiu CF, Lin SF, Lin J, Chang CS, Tien HF, Liu TW, Chen PJ, Cheng AL. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. *Hepatology* 2014; **59**: 2092-2100 [PMID: 24002804 DOI: 10.1002/hep.26718]

58 Matsu T, Kang JH, Nojima M, Tomonari A, Aoki H, Yamazaki H, Yane K, Tsuji K, Ando S, Ando S, Sakai H, Maemori M, Muguchi H, Tanaka Y. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma. *J Med Virol* 2013; **85**: 1900-1906 [PMID: 23296682 DOI: 10.1002/jmv.23694]

59 Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. *Cancer* 2010; **115**: 115-121 [PMID: 19989164 DOI: 10.1002/cncr.24274]

60 Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zhou S. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. *Eur J Haematol* 2010; **85**: 243-250 [PMID: 20491885 DOI: 10.1111/j.1600-0609.2010.01474.x]

61 Koo YX, Tao M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. *Ann Hematol* 2011; **90**: 1219-1223 [PMID: 21520001]

62 Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Rekodipuroto AH, Tan D, Goh YT, Lee J, Intrigumtornechi T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. *Eur J Cancer* 2013; **49**: 3486-3496 [PMID: 23910494 DOI: 10.1016/j.ejca.2013.07.006]

63 Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagioli S, Grossi P, Lamportico P, Meloni R, Mangan A, Puoti M, Raimondo G, Smedile A. Prophylaxis and treatment of hepatitis B in immunocompromised patients. *Dig Liver Dis* 2013; **45**: 397-408 [PMID: 17382608 DOI: 10.1016/j.dld.2012.01.017]

64 Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007; **45**: 507-539 [PMID: 17256718]

65 Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-
Sagnelli E et al. Occult HBV infection in an immunosuppressive setting

analysis. J Clin Virol 2013; 57: 209-214 [PMID: 23562041 DOI: 10.1016/j.jcv.2013.03.010]

Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puotì M, Airò P. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009; 36: 1188-1194 [PMID: 19447932 DOI: 10.3899/jrheum.081246]

Tamović A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011; 46: 556-564 [PMID: 21246383 DOI: 10.1007/s00535-010-0367-5]

Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, Kim TY, Sohn JH, Lee HS. Possible reactivation of potential hepatitis B virus infection due to tumor necrosis factor alpha-blocker in the treatment of rheumatic diseases. J Rheumatol 2010; 37: 346-350 [PMID: 20008922 DOI: 10.3899/jrheum.090436]

Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatoid patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013; 31: 118-121 [PMID: 23111091]

Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha-therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006; 21: 1366-1371 [PMID: 16916178 DOI: 10.1111/j.1440-1746.2006.04559.x]

Biondo MI, Germano V, Pietrosanti M, Canzoni M, Marigiani M, Stroffolini T, Salemi S, D’Amelio R. Lack of hepatitis B virus reactivation after anti-tumor necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies. Eur J Intern Med 2014; 25: 482-484 [DOI: 10.1016/j.ejim.2013.11.014]

Yeo W, Chan HL. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol 2013; 28: 31-37 [PMID: 23020594]

Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ. Comprehensive analysis of risk factors associated with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311 [PMID: 15054446 DOI: 10.1038/sj.bjc.6601699]

Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003; 70: 553-561 [PMID: 12794712 DOI: 10.1002/jmv.10430]

Saitta C, Musolino C, Marabelló G, Martino D, Leonardi MS, Pollicino T, Altavilla G, Raimondo G. Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy. Dig Liver Dis 2013; 45: 683-686 [PMID: 23490440 DOI: 10.1016/j.dld.2013.01.022]

Huang YH, Hsiao LT, Hong YC, Chiu TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tseng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772 [PMID: 23775967 DOI: 10.1200/JCO.2012.48.5938]

Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F, Latero E. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol 2008; 83: 673-675 [PMID: 18528824 DOI: 10.1002/ajh.21214]

Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 2009; 81: 441-445 [PMID: 19152997 DOI: 10.1002/jmv.21422]

Nebbia G, Garcia-Diaz A, Aylliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti AM. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 2007; 79: 1464-1471 [PMID: 17705185 DOI: 10.1002/jmv.20564]

Rodriguez-Torres M, Gonzalez-Garcia J, Bräu N, Solà R, Moreno S, Rockstroh J, Smaill F, Mendes-Correa MC, DePamphilis J, Torriani FJ. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem? J Med Virol 2007; 79: 694-700 [PMID: 17457912]

Pogány K, Zaaijer HL, Pries JM, Wit FW, Lange JM, Beld MG. Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients. AIDS Res Hum Retroviruses 2005; 21: 922-926 [PMID: 16386107 DOI: 10.1089/aid.2005.21.922]

Quarleri J, Moretti F, Bouzou MB, Laufner N, Carrillo MG, Giuliano SF, Perez H, Cahn P, Salomon H. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B: AIDS Res Hum Retroviruses 2007; 23: 525-531 [PMID: 17506609 DOI: 10.1089/aid.2006.0172]

Piroth L, Carrat F, Larrat S, Goderel I, Martha B, Payan C, LuneL-Fabiani F, Bani-Sadr F, Perronne C, Cacoub P, Pol S, Morand P. Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy. J Hepatology 2008; 49: 892-898 [PMID: 18752863 DOI: 10.1016/j.jhep.2008.06.024]

Lo Re V, Frank I, Gross R, Dockter J, Linnen J, Giachetti C, Tébas P, Stern J, Symmsrvedt M, Locasio AR, Kostman JR, Strom BL. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immun Defic Syndr 2007; 44: 315-320 [PMID: 17195655]

Mphahlele MJ, Lukhwarenti A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006; 35: 14-20 [PMID: 15916918 DOI: 10.1016/j.jciv.2005.04.003]

Raffa G, Maimone S, Cargnel A, Santantonio T, Antonucci G, Massari M, Schiavini M, Caccurio G, Pollicino T, Raimondo G. Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS 2007; 21: 2171-2175 [PMID: 18090043]

Castro P, Laguno M, Nomdedeu M, López A, Plana M, Fumero E, Gallart T, Mallojas J, Catell JM, Garcia C. Clinicoimmunological progression and response to treatment of long-term nonprogressor HIV-hepatitis C virus-coinfected patients. AIDS Res Hum Retroviruses 2007; 23: 863-867 [PMID: 17678468 DOI: 10.1089/aid.2006.0251]

Fabricis B, Biasin MR, Giordani MT, Berardo L, Menini V, Carlotto A, Miotti MG, Manfrin V, Baldo V, Nebbia G, Fabris P, Angius PW, Gibson PR. Hepatitis B and C virus infections in HIV-coinfected patients with chronic and occult hepatitis B. J Med Virol 2005; 77: 694-700 [PMID: 15701620 DOI: 10.1002/jmv.20092]

Morsica G, Ancarani F, Bagaglio S, Maracci M, Cicconi P, Cozzi Lepri A, Antonucci G, Bruno R, Santantonio T, Tacconelli L, Baldelli F, Piscopo R, Santoro D, Lazzarin A, D’Arminio Monforte A. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus infection among rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. J Rheumatol 2009; 36: 1188-1194 [PMID: 19447932 DOI: 10.3899/jrheum.081246]
co-infection, virological and immunological features. *Infection* 2009; 37: 445-449 [PMID: 19669092 DOI: 10.1007/s15010-008-8194-9]

105 Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, Sato T, Chiha T. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. *Ann Intern Med* 2007; 146: 649-656 [PMID: 17470833]

106 Marque-Juillet S, Touzard A, Monnier S, Fernand-Laurent C, Therby A, Rigaudeau S, Harzic M. Evaluation of cytomegalovirus quantification in blood by the R-gene real-time PCR test. *Pathol Biol* (Paris) 2010; 58: 162-165 [PMID: 19854587 DOI: 10.1016/j.patbio.2009.07.029]

107 Jardim RN, Gonçalves NS, Pereira JS, Fais VC, Gonçalves Junior FL. Occult hepatitis B virus infection in immunocompromised patients. *Braz J Infect Dis* 2008; 12: 300-305 [PMID: 19030729]

108 Cassini R, De Mitri MS, Gibellini D, Urbinati L, Bagaglio S, Morsica G, Domenicali M, Verucchi G, Bernardi M. A novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infection. *J Viral Hepat* 2013; 20: 42-49 [PMID: 23231083 DOI: 10.1111/j.1365-2893.2012.01623]

P- Reviewers: Sutti S, Tsuchiya A S- Editor: Wen LL
L- Editor: A E- Editor: Liu SQ
